Your browser doesn't support javascript.
loading
ESTRO ACROP and SIOPE recommendations for myeloablative Total Body Irradiation in children.
Hoeben, Bianca A W; Pazos, Montserrat; Seravalli, Enrica; Bosman, Mirjam E; Losert, Christoph; Albert, Michael H; Boterberg, Tom; Ospovat, Inna; Mico Milla, Soraya; Demiroz Abakay, Candan; Engellau, Jacob; Jóhannesson, Vilberg; Kos, Gregor; Supiot, Stéphane; Llagostera, Camille; Bierings, Marc; Scarzello, Giovanni; Seiersen, Klaus; Smith, Ed; Ocanto, Abrahams; Ferrer, Carlos; Bentzen, Søren M; Kobyzeva, Daria A; Loginova, Anna A; Janssens, Geert O.
Afiliação
  • Hoeben BAW; Dept. of Radiation Oncology, University Medical Center Utrecht, The Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Electronic address: b.a.w.hoeben@umcutrecht.nl.
  • Pazos M; Dept. of Radiation Oncology, University Hospital, LMU Munich, Germany.
  • Seravalli E; Dept. of Radiation Oncology, University Medical Center Utrecht, The Netherlands.
  • Bosman ME; Dept. of Radiation Oncology, University Medical Center Utrecht, The Netherlands.
  • Losert C; Dept. of Radiation Oncology, University Hospital, LMU Munich, Germany.
  • Albert MH; Dept. of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Germany.
  • Boterberg T; Dept. of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
  • Ospovat I; Dept. of Radiation Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Mico Milla S; Dept. of Radiation Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Demiroz Abakay C; Dept. of Radiation Oncology, Uludag University Faculty of Medicine Hospital, Bursa, Turkey.
  • Engellau J; Dept. of Radiation Oncology, Skåne University Hospital, Lund, Sweden.
  • Jóhannesson V; Dept. of Radiation Oncology, Skåne University Hospital, Lund, Sweden.
  • Kos G; Dept. of Radiation Oncology, Institute of Oncology Ljubljana, Slovenia.
  • Supiot S; Dept. of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes St. Herblain, France.
  • Llagostera C; Dept. of Medical Physics, Institut de Cancérologie de l'Ouest, Nantes St. Herblain, France.
  • Bierings M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Scarzello G; Dept. of Radiation Oncology, Veneto Institute of Oncology-IRCCS, Padua, Italy.
  • Seiersen K; Danish Centre for Particle Therapy, Aarhus, Denmark.
  • Smith E; Dept. of Radiation Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Ocanto A; Dept. of Radiation Oncology, La Paz University Hospital, Madrid, Spain.
  • Ferrer C; Dept. of Medical Physics and Radiation Protection, La Paz University Hospital, Madrid, Spain.
  • Bentzen SM; Dept. of Epidemiology and Public Health, Division of Biostatistics and Bioinformatics, University of Maryland School of Medicine, Baltimore, United States.
  • Kobyzeva DA; Dept. of Radiation Oncology, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
  • Loginova AA; Dept. of Radiation Oncology, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
  • Janssens GO; Dept. of Radiation Oncology, University Medical Center Utrecht, The Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Radiother Oncol ; 173: 119-133, 2022 08.
Article em En | MEDLINE | ID: mdl-35661674
ABSTRACT
BACKGROUND AND

PURPOSE:

Myeloablative Total Body Irradiation (TBI) is an important modality in conditioning for allogeneic hematopoietic stem cell transplantation (HSCT), especially in children with high-risk acute lymphoblastic leukemia (ALL). TBI practices are heterogeneous and institution-specific. Since TBI is associated with multiple late adverse effects, recommendations may help to standardize practices and improve the outcome versus toxicity ratio for children. MATERIAL AND

METHODS:

The European Society for Paediatric Oncology (SIOPE) Radiotherapy TBI Working Group together with ESTRO experts conducted a literature search and evaluation regarding myeloablative TBI techniques and toxicities in children. Findings were discussed in bimonthly virtual meetings and consensus recommendations were established.

RESULTS:

Myeloablative TBI in HSCT conditioning is mostly performed for high-risk ALL patients or patients with recurring hematologic malignancies. TBI is discouraged in children <3-4 years old because of increased toxicity risk. Publications regarding TBI are mostly retrospective studies with level III-IV evidence. Preferential TBI dose in children is 12-14.4 Gy in 1.6-2 Gy fractions b.i.d. Dose reduction should be considered for the lungs to <8 Gy, for the kidneys to ≤10 Gy, and for the lenses to <12 Gy, for dose rates ≥6 cGy/min. Highly conformal techniques i.e. TomoTherapy and VMAT TBI or Total Marrow (and/or Lymphoid) Irradiation as implemented in several centers, improve dose homogeneity and organ sparing, and should be evaluated in studies.

CONCLUSIONS:

These ESTRO ACROP SIOPE recommendations provide expert consensus for conventional and highly conformal myeloablative TBI in children, as well as a supporting literature overview of TBI techniques and toxicities.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Irradiação Corporal Total / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Child / Child, preschool / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Irradiação Corporal Total / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Child / Child, preschool / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article